Keeling Stephanie O, Oswald Anna E
Division of Rheumatology, Department of Medicine, University of Alberta, 562 Heritage Medical Research Center, Edmonton, Alberta, Canada.
Clin Rheumatol. 2009 Jan;28(1):1-9. doi: 10.1007/s10067-008-1031-9. Epub 2008 Nov 6.
Pregnancy is an important condition that can affect and be affected by rheumatic disease. Overall, pregnancy is viewed as a Th2-predominant state, but several Th1-related cytokines are vital to early pregnancy. In rheumatoid arthritis for example, the majority of women improve by the beginning of the second trimester, but the majority (90%) will flare in the first 3 to 4 months postpartum. In contrast, systemic lupus erythematosus has an unpredictable course in pregnancy, leaving most rheumatologists to recommend a disease-quiescent state prior to conception. Other diseases such as scleroderma are less clear because the disease less commonly presents in the childbearing period. Many immunosuppressive medications for the rheumatic diseases are contraindicated in pregnancy because of their mechanisms of action leaving only a select few "safe" medications. Significant heterogeneity between the Food and Drug Administration (FDA) category for a medication and what a rheumatologist does in clinic leads to confusion on how a patient should be treated for active rheumatic disease both peripartum and postpartum, particularly if the patient is breastfeeding. We review the general state of pregnancy and how it is affected by prototypical rheumatic diseases including rheumatoid arthritis and systemic lupus erythematosus. In addition, we present the most commonly used disease-modifying antirheumatic drugs and immunosuppressants and explain the difference between the FDA category and clinical practice among rheumatologists. Finally, we provide some general recommendations on how to manage a rheumatic disease during pregnancy including: (a) preconception planning to ensure no teratogenic medications on board, (b) early disclosure of pregnancy to all caregivers including the rheumatologist, family physician, obstetrician, and maternal-fetal medicine specialist, and (c) planning of safe medication use for acute flare-ups and disease suppression peripartum and postpartum.
妊娠是一种重要的情况,可影响风湿性疾病并受其影响。总体而言,妊娠被视为以Th2为主导的状态,但几种与Th1相关的细胞因子对早期妊娠至关重要。例如,在类风湿关节炎中,大多数女性在孕中期开始时病情改善,但大多数(90%)会在产后前3至4个月病情复发。相比之下,系统性红斑狼疮在妊娠期间的病程不可预测,这使得大多数风湿病学家建议在受孕前疾病处于静止状态。其他疾病如硬皮病则不太明确,因为该疾病在育龄期较少出现。许多用于治疗风湿性疾病的免疫抑制药物在妊娠期间是禁忌的,因为它们的作用机制,导致只有少数几种“安全”药物。药物的美国食品药品监督管理局(FDA)分类与风湿病学家在临床中的做法之间存在显著差异,这导致在围产期和产后如何治疗患有活动性风湿性疾病的患者产生困惑,特别是如果患者正在母乳喂养。我们回顾了妊娠的一般情况以及它如何受到典型风湿性疾病(包括类风湿关节炎和系统性红斑狼疮)的影响。此外,我们介绍了最常用的改善病情抗风湿药物和免疫抑制剂,并解释了FDA分类与风湿病学家临床实践之间的差异。最后,我们提供了一些关于如何在妊娠期间管理风湿性疾病的一般建议,包括:(a)孕前计划以确保体内没有致畸药物,(b)尽早向所有护理人员(包括风湿病学家、家庭医生、产科医生和母胎医学专家)披露妊娠情况,以及(c)计划在围产期和产后安全使用药物以应对急性发作和控制疾病。